Literature DB >> 15816871

Histone deacetylase inhibitors decrease reelin promoter methylation in vitro.

Colin P Mitchell1, Ying Chen, Marija Kundakovic, Erminio Costa, Dennis R Grayson.   

Abstract

We investigated the effects of agents that induce reelin mRNA expression in vitro on the methylation status of the human reelin promoter in neural progenitor cells (NT2). NT2 cells were treated with the histone deacetylase inhibitors, trichostatin A (TSA) and valproic acid (VPA), and the methylation inhibitor aza-2'-deoxycytidine (AZA) for various times. All three drugs reduced the methylation profile of the reelin promoter relative to untreated cells. The acetylation status of histones H3 and H4 increased following treatment with VPA and TSA at times as short as 15 min following treatment; a result consistent with the reported mode of action of these drugs. Chromatin immunoprecipitation experiments showed that these changes were accompanied by changes occurring at the level of the reelin promoter as well. Interestingly, AZA decreased reelin promoter methylation without concomittantly increasing histone acetylation. In fact, after prolonged treatments with AZA, the acetylation status of histones H3 and H4 decreased relative to untreated cells. We also observed a trend towards reduced methylated H3 after 18 h treatment with TSA and VPA. Our data indicate that while TSA and VPA act to increase histone acetylation and reduce promoter methylation, AZA acts only to decrease the amount of reelin promoter methylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816871     DOI: 10.1111/j.1471-4159.2005.03040.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

Review 1.  Epigenetic GABAergic targets in schizophrenia and bipolar disorder.

Authors:  A Guidotti; J Auta; Y Chen; J M Davis; E Dong; D P Gavin; D R Grayson; F Matrisciano; G Pinna; R Satta; R P Sharma; L Tremolizzo; P Tueting
Journal:  Neuropharmacology       Date:  2010-11-11       Impact factor: 5.250

2.  Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.

Authors:  E Dong; R C Agis-Balboa; M V Simonini; D R Grayson; E Costa; A Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-19       Impact factor: 11.205

3.  c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.

Authors:  Guochun Jiang; Amy Espeseth; Daria J Hazuda; David M Margolis
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

4.  Reelin promoter hypermethylation in schizophrenia.

Authors:  Dennis R Grayson; Xiaomei Jia; Ying Chen; Rajiv P Sharma; Colin P Mitchell; Alessandro Guidotti; Erminio Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-16       Impact factor: 11.205

5.  The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.

Authors:  M V Simonini; L M Camargo; E Dong; E Maloku; M Veldic; E Costa; A Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

6.  Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder.

Authors:  Marin Veldic; Bashkim Kadriu; Ekrem Maloku; Roberto C Agis-Balboa; Alessandro Guidotti; John M Davis; Erminio Costa
Journal:  Schizophr Res       Date:  2007-01-31       Impact factor: 4.939

Review 7.  Histone modifications, DNA methylation, and schizophrenia.

Authors:  David P Gavin; Rajiv P Sharma
Journal:  Neurosci Biobehav Rev       Date:  2009-10-30       Impact factor: 8.989

Review 8.  Epigenetics and the transition from acute to chronic pain.

Authors:  Thomas Buchheit; Thomas Van de Ven; Andrew Shaw
Journal:  Pain Med       Date:  2012-09-14       Impact factor: 3.750

Review 9.  Current status and future prospects for epigenetic psychopharmacology.

Authors:  Marco P Boks; Noëlle M de Jong; Martien J H Kas; Christiaan H Vinkers; Cathy Fernandes; René S Kahn; Jonathan Mill; Roel A Ophoff
Journal:  Epigenetics       Date:  2012-01-01       Impact factor: 4.528

10.  Reelin is a target of polyglutamine expanded ataxin-7 in human spinocerebellar ataxia type 7 (SCA7) astrocytes.

Authors:  Shaun D McCullough; Xiaojiang Xu; Sharon Y R Dent; Stefan Bekiranov; Robert G Roeder; Patrick A Grant
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.